NEW
YORK, Jan. 23, 2024 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, today announced that Gerard
Michel, CEO, will participate in a fireside chat moderated
by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the
Lytham Partners 2024 Investor Select Conference. Management will
also host virtual one-on-one meetings with investors.
Company Webcast
The webcasted fireside chat will take place at 8:45 AM ET on
Thursday, February 1, 2024. The
webcast can be accessed at
https://wsw.com/webcast/lytham10/dcth/2073328 or on the Company's
website at delcath.com. The webcast will also be available for
replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings
throughout the event. To arrange a meeting with management, please
contact Lytham Partners at 1x1@lythampartners.com or register for
the event at https://lythampartners.com/select2024invreg/.
Further information on the conference is available at
https://lythampartners.com/select2024.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary products, HEPZATO KIT (melphalan for
Injection/Hepatic Delivery System), approved for use in the
United States by FDA, and CHEMOSAT Hepatic Delivery System for
Melphalan percutaneous hepatic perfusion, designated under the
medical device regulation for use in Europe and
the United Kingdom, are designed to administer high-dose
chemotherapy to the liver while controlling systemic exposure and
associated side effects during a PHP procedure.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-a-fireside-chat-at-the-lytham-partners-2024-investor-select-conference-302041094.html
SOURCE Delcath Systems, Inc.